Pdl1 Expression News Today

Dr Noor Abuhadra discusses the various first-line treatment options for metastatic TNBC, highlighting the importance of PDL1 expression for immunotherapy and germline testing for targeted therapies like PARP inhibitors. Patient Shay Elkins shares her treatment journey, from her initial chemo and immunotherapy to surgical intervention, emphasizing the importance of a collaborative approach with her healthcare team and the supportive role of nursing staff.

Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.

Shared insight on the value that molecular testing and PDL1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.

Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.

Focused discussion on the selection of neoadjuvant therapy in patients with resectable NSCLC in light of recent clinical trials.